Phase 2 N=112 ALL Adult Consortium Trial: Adult ALL Trial
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 43; 79 Percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,856 Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
Diabetes Mellitus · Cardiovascular Diseases
Primary: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both — 1279; 1318 Participants
N/A N=25 Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
Pediatric Acute Lymphoblastic Leukemia · Leukemia · Acute Lymphoblastic Leukemia
Primary: Enrollment Rate of Participants — 25 Participants
N/A N=200 AMPLATZER Duct Occluder II Additional Sizes
Patent Ductus Arteriosus
Primary: Safety Endpoint: The Rate of Major Complications After an Attempted ADO II AS Device Implant — 0; 2.8 percentage of participants
Phase 1 N=24 AC220 for Children With Relapsed/Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
N/A N=589 Latin American Real-world Study in Acute Leukemia
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Phase 2 N=100 A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 63 Percentage of patients
N/A N=123 Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=106 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects
Phase 2 N=30 Treatment of Older Adults With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Overall Survival at One Year — 19 Participants
N/A N=51 All About Me: An Intervention to Ease the Transition to Long Term Care
Dementia · Alzheimer Disease · Dementia, Vascular
Primary: Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale — 0.83 score on a scale — p=<0.01
Phase 3 N=167 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Acute Lymphoblastic Leukemia · Lymphoblastic Leukemia
Primary: Response Rate During the First Course of JZP-458 Administration — 18; 70; 44; 20 Participants
Phase 2 N=73 ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Food Allergy
Primary: 600mg Desensitization in at Least One Qualifying Food — 8; 11; 4 Participants
Phase 2 N=65 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Alzheimer's Disease · Healthy Non-elderly and Elderly Adults
Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
N/A N=43 PureWick™ Adolescent Study
Healthy Volunteers, Adolescent
Primary: Performance of the PureWick System in Adolescents After HCP Placement and Self-placement — 90.40; 93.09; 87.15; 90.41 Percentage of urine captured
Phase 2 N=38 NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Acute
Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants
Phase 1 N=12 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Phase 2 N=12 Use of ACTIMMUNE in Patients With ADO2
Autosomal Dominant Osteopetrosis Type 2
Primary: Changes in Bone Resorption Markers From Baseline to 14 Weeks. — 2.2; -2.1 percentage of change
N/A N=177 A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Liver Diseases · Hepatocellular Cancer · Endstage Liver Disease
Primary: Living Donor Pain Management — 2.62; 2.56; 2.87; 2.67 Scores on Visual Analogue Pain Scale
Phase 2 N=54 Multiple Doses of AT-1501-A201 in Adults With ALS
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability — 8; 8; 10; 16 participants
N/A N=28 Pediatric Ease of Use ELLIPTA Items
Asthma
Primary: Number of Pediatric Participants With Problems Understanding Item Wording-Round 1 Interviews — 0; 0 Participants
Phase 3 N=74 Phase III B in Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
N/A N=95 Adapting Diet and Action for Everyone (ADAPT+)
Pediatric Obesity
Primary: Acceptability — 3.91; 3.85 score on a scale
Phase 2 N=46 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants
Phase 3 N=253 Adolescent Mite Allergy Safety Evaluation
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects
Phase 3 N=30 The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
Rhinitis · Asthma · Allergy
Primary: Change in Symptoms Score After Nasal Allergen Challenge — -5; -4; -1 score on a scale
Phase 2 N=19 Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
Adult Lymphoblastic Lymphoma
Primary: Percentage of Subjects Disease-free Survival — 63.2 percentage of participants
Phase 2 N=15 CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
B Acute Lymphoblastic Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Acute Lymphoblastic Leukemia
Primary: Number of Patients With Grade 3-5 Toxicities Occurring Within the Dose Limiting Toxicity (DLT) Period of AUTO3 Infusion — 4; 4; 6 Participants